Julia G. Butchko - 02 Apr 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Chief Development Officer
Issuer ticker: IMVT
Reported as of: 02 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2024, 16:29:12 UTC
Prior SEC filing: 23 Feb 2024
Next SEC filing: 10 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Eva Renee Barnett, attorney-in-fact for Julia G. Butchko

Key filing fact

Julia G. Butchko filed Form 4 for Immunovant, Inc. (IMVT) on 04 Apr 2024.

Key facts

This page summarizes Julia G. Butchko's Form 4 filing for Immunovant, Inc. (IMVT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2024, 16:29.

Change

Previous filing in this sequence was filed on 23 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Award

Transaction value: $0
Shares: +54,978
Change %: +13%
Price: $0.000000
Shares after: 462,795
Date: 02 Apr 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +68,723
Change %
Price: $0.000000
Shares after: 68,723
Date: 02 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,723
Exercise price: $30.78
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Footnote F2

The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.